Safety has not been established during pregnancy; according to some experts, use should be avoided as a precautionary measure.

AU TGA pregnancy category: B1
US FDA pregnancy category: Not assigned.

Risk summary: There is insufficient data on the use of this drug in pregnant women to inform a drug-related risk to the mother or the fetus.

Animal studies have failed to reveal evidence of embryolethality, fetotoxicity, teratogenicity, or abnormal early embryonic development at higher doses. There are no controlled data in human pregnancy.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Safety has not been established.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

Comments:
-Developmental and health benefits of breastfeeding should be considered as well as the mother's clinical need for this drug.
-Potential side effects in the breastfed child due to the drug or the mother's underlying condition should be considered.

See references